IDEAYA Biosciences (STU:30J) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:30J IDEAYA Biosciences Inc STU:30J
50 GF Score
Price €32.06
GF Value €170.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:30J
50GF Score
IDEAYA Biosciences Inc STU:30J
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IDEAYA Biosciences (STU:30J) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of €32.06 is trading 81.2% below its estimated GF Value™ of €170.83. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for STU:30J:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €170.83 vs. price of €32.06 (81.2% below fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the STU:30J stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEAYA Biosciences Business Description

Other Exchanges IDYA:USA
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
50GF Score

Get the complete analysis for STU:30J

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.06
Price
€170.83
GF Value